A Phase 3 interventional study of DA-005 and Topical minoxidil 5% in Androgenetic Alopecia, Female Pattern Baldness and Male Pattern Baldness, sponsored by Applied Biology, Inc.. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Applied Biology, Inc. · Phase 3, Interventional, and Treatment
Sponsor change of formulation
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Alopecia by Applied Biology, Inc. — 3 open to participants now, 3 under way, 2 of them phase 3. Alopecia · Applied Biology, Inc..
Among the 13 studies in Alopecia by Applied Biology, Inc., this one is one of 3 that started in 2027, is one of 3 in phase 3, and was the 8th registered.
512 studies on the registry are indexed under Alopecia; 127 are open to participants now.
Browse Alopecia studies →3 of the 13 studies in Alopecia by Applied Biology, Inc. are open now, in 2 countries. Recruiting first, the newest first:
Applied Biology, Inc. · Sites in Brazil, Italy
Ages 18–65 · Women only
Applied Biology, Inc. · Sites in Italy
Ages 18–65 · Women only
Applied Biology, Inc.
Ages 18+
By country, each count listing its studies:
Of the 75 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 47 (63%) stop at 75 or younger; 10 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 4
First in 2014; this study’s year is marked. 3 started in 2027.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 60 across the 9 interventional studies, 150 across the 4 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
Applied Biology, Inc. is the lead sponsor of 25 studies on the registry; 5 are open to participants now.
2 of the studies in Alopecia by Applied Biology, Inc. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06648850Phase 3Applied Biology, Inc.Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth | 2027-03-19 |
| NCT07397325Applied Biology, Inc.Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia | 2027-02-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Alopecia by Applied Biology, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to assess the safety and efficacy of DA-005 and DA-002 as a treatment for hair loss (androgenetic alopecia).
DA-005 is a botanical supplement with demonstrated HIF-1a inhibitory action. The ingredients were tested in-vitro and have demonstrated the HIF-1a inhibitory effect. The primary aim of the study is to compare DA-005 to topical minoxidil in the treatment of hair loss (also known as androgenetic alopecia).
DA-002 is a topical alpha 1 agonist. The ingredients were tested in-vitro and have demonstrated hair growth effects. The secondary aim of the study is to compare DA-002 to topical minoxidil in the treatment of hair loss (also known as androgenetic alopecia).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral Botanical Supplement HIF-1a inhibitor
Dietary Supplement: DA-005 · Other: Placebo Topical Solution
Topical Minoxidil 5%
Drug: Topical minoxidil 5% · Dietary Supplement: Placebo Oral Tablet
Topical Alpha 1 Agonist
Drug: DA-002 · Dietary Supplement: Placebo Oral Tablet
Oral Botanical Supplement HIF-1a inhibitor
Also known as: Daniel Alain Botanical Supplement Treatment for Hair Loss
Topical minoxidil 5%
Topical Alpha 1 Agonist (GRAS)
Placebo Oral Tablet
Placebo Topical Solution
Target Area Hair Counts
Target Area Hair Counts
Time frame: Week [0,12]
Target Area Hair Counts
Target Area Hair Counts
Time frame: Week [0,24]
No study locations are listed for this record.
Plan to share: No
Start is estimated for Jan 2027; primary completion for Oct 2027, 9 months later.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Jan 2025 → Jan 2027, primary completion Oct 2025 → Oct 2027 and completion Dec 2025 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Sponsor change of formulation
Sponsor change of formulation
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.